Overview of antidiabetic drug use in type-2 diabetes mellitus patients in the outpatient installation of the Islamic University of Indonesia Hospital

Authors

  • Muhammad Galih Fajrin R. Program Studi Farmasi, Fakultas Sains dan Teknologi, Universitas PGRI Yogyakarta
  • Rahmat A Hi Wahid Program Studi Farmasi, Fakultas Sains dan Teknologi, Universitas PGRI Yogyakarta

DOI:

https://doi.org/10.21111/pharmasipha.v9i2.12518

Abstract

Diabetes mellitus (DM) is a chronic disease that occurs when the pancreas does not produce enough insulin or the body does not use the insulin that is made efficiently. The prevalence of DM in Indonesia has increased from 6.9% in 2013 to 8.5% in 2018. Meanwhile, in the Special Region of Yogyakarta in 2021 there were 83,568 patients, and Bantul Regency had 15,727 DM patients. This study aimed to describe the use of antidiabetic drugs in outpatient type 2 DM patients at the UII Hospital, Yogyakarta from January to June 2023. This research method is non-experimental research. Data collection was retrospective by taking medical record data of outpatients from January to June 2023. Sampling using purposive sampling method so that 92 samples were obtained. The results obtained antidiabetic drugs most commonly used in combination therapy are metformin and glimepiride as many as 25 cases (60%) and in single therapy the most commonly used drug is metformin with 22 cases (44%). The study concluded that antidiabetic therapy used at the UII Hospital, Yogyakarta was sulfonylurea and biguanid groups as many as 25 cases (60%) in combination therapy and sulfonylurea groups as many as 22 cases (44%) in single therapy.  Keywords: antidiabetics, type 2 diabetes mellitus, hospital

Downloads

Published

2025-04-26

Issue

Vol. 9 No. 2 (2025): September

Section

Articles

License

Copyright (c) 2025 Muhammad Galih Fajrin R., Rahmat A Hi Wahid

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors who publish with this Journal agree to the following terms:

  1. Author retain copyright and grant the journal right of first publication with the work simultaneously licensed under a creative commons attribution license that allow others to share the work within an acknowledgement of the work’s authorship and initial publication of this journal.
  2. Authors are able to enter into separate, additional contractual arrangement for the non-exclusive distribution of the journal’s published version of the work (e.g. acknowledgement of its initial publication in this journal).
  3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published works.